Welcome to our dedicated page for Manhattan Scientifics news (Ticker: MHTX), a resource for investors and traders seeking the latest updates and insights on Manhattan Scientifics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Manhattan Scientifics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Manhattan Scientifics's position in the market.
Summary not available.
Summary not available.
Manhattan Scientifics Inc. (OTCQB: MHTX) announced positive early results from the human study of Imagion Biosystems' cancer diagnostic technology. Following the announcement, shares of Imagion Biosystems (IBX.AX) surged by 46%, reaching 71 million in trading volume. Manhattan Scientifics owns over 50 million shares of Imagion, indicating a significant investment in the company’s future. The press release highlights the innovative diagnostic technology aimed at early cancer detection, emphasizing its non-radioactive and super-sensitive nature.
Manhattan Scientifics Inc. (OTC: QB) holds over 50 million shares of Imagion Biosystems (IBX.AX), focused on developing advanced non-radioactive cancer imaging technology. A televised interview with Imagion's CEO, Bob Proulx, is highlighted, discussing their innovative diagnostic solutions aimed at early cancer detection. The press release emphasizes the partnership and technology transfer efforts with Los Alamos and Sandia National Laboratories in New Mexico. The company warns that investments are high risk, with future results uncertain, stressing forward-looking statements are not guarantees of performance.
Manhattan Scientifics Inc. (OTCQB: MHTX) has invested $30 million and committed to a 10-year effort to commercialize a non-invasive cancer diagnostic in partnership with MD Anderson Cancer Center. The company is currently awaiting regulatory approval to commence human trials. The CEO expressed intentions to enhance shareholder value, despite the company's market cap fluctuations, which have seen a peak near $1 billion and a low of $17 million.
Manhattan Scientifics Inc. (OTCQB: MHTX) announced year-end updates on its Nano-Medicine Cancer and Nano-Medical Metal Alloy initiatives. The company owns over 50 million shares of Imagion Biosystems Ltd. (ASX: IBX), which has made significant progress, including establishing clinical trials and increasing cash reserves to $10.13 million. MHTX also anticipates royalties from its licensed nano-metal technology for medical prosthetics, expecting to start earning in 2021. Management emphasizes low overhead and a strong commitment to the company's growth.
FAQ
What is the current stock price of Manhattan Scientifics (MHTX)?
What is the market cap of Manhattan Scientifics (MHTX)?
